Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
15.21
-1.76 (-10.37%)
Arrowhead Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapeutics aimed at treating diseases through RNA interference (RNAi) technology
The company's primary goal is to create targeted treatments that can silence specific genes associated with various diseases, particularly in the areas of liver diseases, cancer, and cardiovascular conditions. Arrowhead's proprietary platform allows for the design of treatments that can effectively deliver small interfering RNA (siRNA) to relevant tissues, potentially leading to transformative therapies that address unmet medical needs. Through its research and development efforts, Arrowhead aims to advance its pipeline of drug candidates and bring novel solutions to the market for patients suffering from challenging health conditions.
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Arrowhead Pharmaceuticals Inc. (NASDAQARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. NASDAQ: SRPTNASDAQSRPT)
Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it presented preclinical data on ARO-INHBE.
Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.
